STOCK TITAN

Zimmer Biomet Holdings (ZBH) Financials

ZBH NYSE
Trailing 12 months to September 30, 2026
Revenue $8.6B +7.0% YoY
Net Income $767.4M -4.7% YoY
EPS (Diluted) $3.96 -1.7% YoY
Free Cash Flow $1.6B +10.7% YoY
Market Cap $19.3B as of Nov 17, 2026
Price / Sales 2.3x on $8.6B revenue, trailing 12 months to September 30, 2026
Price / Earnings 25.2x on $767.4M net income, trailing 12 months to September 30, 2026
Price / Book 1.5x on $12.7B equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 17, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 4, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ZBH SEC filings page.

Zimmer Biomet Holdings, Inc. (ZBH) reported $8.6B in revenue over the twelve months to Sep 30, 2026, up 7.0% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ZBH FY2025

Revenue is growing, but FY2025 shows margin compression and heavier debt while cash generation remains more resilient than reported earnings.

Growth is not translating into operating profit: revenue rose 7.2% from FY2024 to FY2025 while operating income fell 14.6%. Gross margin fell 1.7 pp as SG&A rose 11.2%, pointing to cost pressure rather than better overhead absorption.

The earnings-to-cash relationship improved sharply: net income fell 22.0% while operating cash flow rose 13.2% in FY2025. Operating cash flow reached $1.70B against net income of $705M, so cash conversion was stronger than the income statement, though the gap can reflect noncash charges and working-capital timing.

Debt expanded faster than the asset base: debt increased 29.8% while total assets rose 8.1% in FY2025. Debt-to-equity reached 0.5x from 0.4x in FY2024, while near-term coverage improved; liquidity and solvency moved in different directions.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Profitability Growth Leverage Liquidity CashFlow Returns 60 / 100
Financial Health Score 60/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Zimmer Biomet Holdings, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability
75

Profitability ranks operating companies on their operating margin with gains on asset sales taken out, averaged over the last three fiscal years with the newest counting most, and in smaller part on how steady that margin has been. Zimmer Biomet Holdings, Inc. scores 75/100 on it among other operating companies.

Growth
51

Growth ranks operating companies on the yearly rate at which revenue compounded across the last three fiscal years (the last two where the earliest reports no revenue), counted in the currency each company reports in so that a move in the exchange rate is not read as growth. Zimmer Biomet Holdings, Inc. scores 51/100 on it among other operating companies.

Leverage
31

Zimmer Biomet Holdings, Inc.'s net debt of $6.3B, being $6.9B of long-term debt less $591.9M of cash, came to 2.89 times its EBITDA in fiscal year 2025. Operating companies are ranked here on long-term debt less cash against their EBITDA, where a lower multiple is the safer one, and Zimmer Biomet Holdings, Inc. scores 31/100 among other operating companies measured the same way.

Liquidity
59

Zimmer Biomet Holdings, Inc. held $1.98 of current assets for every $1 of current liabilities at the end of fiscal year 2025, a current ratio of 1.98. Liquidity ranks operating companies on that ratio, and Zimmer Biomet Holdings, Inc. scores 59/100 among other operating companies.

Cash Flow
83

Cash Flow ranks operating companies on their free cash flow margin, which is operating cash flow less capital spending as a share of revenue, averaged over the last three fiscal years with the newest weighted most. Zimmer Biomet Holdings, Inc. scores 83/100 on it among other operating companies.

Returns
59

Returns ranks operating companies on their return on capital employed, which is operating income against total assets less current liabilities, averaged over three fiscal years with the newest weighted most, and in smaller part on how steady that return has been. Zimmer Biomet Holdings, Inc. scores 59/100 on it among other operating companies.

Altman Z-Score Grey Zone
2.47

Zimmer Biomet Holdings, Inc. scores 2.47, placing it in the grey zone between 1.81 and 2.99. The largest contribution to the score comes from a market capitalization of $19.3B against total liabilities of $10.4B. This signals moderate financial risk that warrants monitoring.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Neutral
5/9

Zimmer Biomet Holdings, Inc. passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Cash-Backed
2.41x

For every $1 of reported earnings, Zimmer Biomet Holdings, Inc. generates $2.41 in operating cash flow ($1.7B OCF vs $705.1M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$2.1B
YoY+3.1%
QoQ-5.2%
5Y CAGR+4.1%
10Y CAGR+1.2%

Zimmer Biomet Holdings, Inc. generated $2.1B in revenue in Q3 2026. This represents an increase of 3.1% from the same quarter a year earlier. Against the prior quarter it is down 5.2%.

EBITDA
$589.6M
YoY-7.1%
QoQ-1.2%
5Y CAGR+4.4%

Zimmer Biomet Holdings, Inc.'s EBITDA was $589.6M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 7.1% from the same quarter a year earlier. Against the prior quarter it is down 1.2%.

Net Income
$191.6M
YoY-17.0%
QoQ-3.4%
5Y CAGR+5.6%
10Y CAGR+1.9%

Zimmer Biomet Holdings, Inc. reported $191.6M in net income in Q3 2026. This represents a decrease of 17.0% from the same quarter a year earlier. Against the prior quarter it is down 3.4%.

EPS (Diluted)
$1.00
YoY-13.8%
QoQ-2.9%
5Y CAGR+7.7%
10Y CAGR+2.5%

Zimmer Biomet Holdings, Inc. earned $1.00 per diluted share (EPS) in Q3 2026. This represents a decrease of 13.8% from the same quarter a year earlier. Against the prior quarter it is down 2.9%.

Cash & Balance Sheet

Free Cash Flow
$484.2M
YoY+33.1%
QoQ+23.0%
5Y CAGR+5.0%
10Y CAGR+5.0%

Zimmer Biomet Holdings, Inc. generated $484.2M in free cash flow in Q3 2026, representing cash available after capex. This represents an increase of 33.1% from the same quarter a year earlier. Against the prior quarter it is up 23.0%.

Cash & Debt
$399.9M
YoY-69.1%
QoQ-2.5%
5Y CAGR-15.3%
10Y CAGR-1.7%

Zimmer Biomet Holdings, Inc. held $399.9M in cash against $6.2B in long-term debt as of Q3 2026.

Dividends Per Share
$0.24
YoY0.0%
QoQ0.0%
5Y CAGR0.0%
10Y CAGR0.0%

Zimmer Biomet Holdings, Inc. paid $0.24 per share in dividends in Q3 2026. That is unchanged from the same quarter a year earlier. It is unchanged from the prior quarter.

Shares Outstanding
189M
YoY-4.5%
QoQ-0.8%
5Y CAGR-2.0%
10Y CAGR-0.6%

Zimmer Biomet Holdings, Inc. had 189M shares outstanding in Q3 2026. This represents a decrease of 4.5% from the same quarter a year earlier. Against the prior quarter it is down 0.8%.

Margins & Returns

Gross Margin
71.2%
YoY-0.9pp
QoQ+0.4pp
5Y change+0.3pp
10Y change+6.3pp

Zimmer Biomet Holdings, Inc.'s gross margin was 71.2% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is down 0.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.4 percentage points.

Operating Margin
14.9%
YoY-2.6pp
QoQ-0.1pp
5Y change+0.5pp

Zimmer Biomet Holdings, Inc.'s operating margin was 14.9% in Q3 2026, reflecting core business profitability. This is down 2.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.1 percentage points.

Net Margin
9.3%
YoY-2.3pp
QoQ+0.2pp
5Y change+0.6pp
10Y change+0.6pp

Zimmer Biomet Holdings, Inc.'s net profit margin was 9.3% in Q3 2026, showing the share of revenue converted to profit. This is down 2.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.2 percentage points.

Return on Equity
1.5%
YoY-0.3pp
QoQ-0.1pp
5Y change+0.4pp
10Y change-0.1pp

Zimmer Biomet Holdings, Inc.'s quarterly ROE was 1.5% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 0.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.1 percentage points.

Capital Allocation

R&D Spending
$105.9M
YoY-8.6%
QoQ+1.0%
5Y CAGR+2.5%

Zimmer Biomet Holdings, Inc. invested $105.9M in research and development in Q3 2026. This represents a decrease of 8.6% from the same quarter a year earlier. Against the prior quarter it is up 1.0%.

Share Buybacks
$78.5M
YoYn/m
QoQ-68.7%

Zimmer Biomet Holdings, Inc. spent $78.5M on share buybacks in Q3 2026, returning capital to shareholders by reducing shares outstanding. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is down 68.7%.

Capital Expenditures
$75.8M
YoY+37.8%
QoQ+39.9%
5Y CAGR+11.5%
10Y CAGR+3.0%

Zimmer Biomet Holdings, Inc. invested $75.8M in capex in Q3 2026, funding long-term assets and infrastructure. This represents an increase of 37.8% from the same quarter a year earlier. Against the prior quarter it is up 39.9%.

ZBH Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ZBH quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Revenue$2.1B+3.1%$2.2B+4.8%$2.1B+9.3%$2.2B+10.9%$2.0B+9.7%$2.1B+7.0%$1.9B+1.1%$2.0B+4.3%
Cost of Revenue$594.5M+6.3%$635.5M+7.3%$576.2M+4.8%$792.4M+35.1%$559.3M+3.8%$592.2M+7.0%$549.8M+7.3%$586.7M+8.9%
Gross Profit$1.5B+1.8%$1.5B+3.8%$1.5B+11.1%$1.5B+1.0%$1.4B+12.2%$1.5B+7.0%$1.4B-1.3%$1.4B+2.5%
R&D Expenses$105.9M-8.6%$104.8M-7.5%$103.4M-6.5%$118.7M+9.4%$115.9M+3.9%$113.3M+3.6%$110.6M+2.5%$108.5M-4.2%
SG&A Expenses$855.0M+5.4%$899.3M+10.4%$849.9M+12.0%$872.2M+16.8%$811.4M+14.3%$814.8M+10.5%$758.8M+3.1%$746.8M+3.4%
Operating Income$307.6M-12.4%$326.1M+8.7%$373.2M+27.7%$154.5M-60.3%$351.3M+25.7%$300.0M-14.6%$292.3M+9.9%$389.0M+9.8%
EBITDA$589.6M-7.1%$596.9M+4.4%$643.2M+17.7%$438.5M-32.8%$634.9M+19.7%$571.8M-3.8%$546.7M+8.4%$652.6M+9.6%
Income Tax$37.2M-22.5%$55.5M-22.1%$63.0M+35.5%-$40.0M-181.8%$48.0Mn/m$71.2M+20.5%$46.5M+9.9%$48.9Mn/m
Net Income$191.6M-17.0%$198.3M+29.8%$238.1M+30.8%$139.4M-41.8%$230.9M-7.3%$152.8M-37.1%$182.0M+5.6%$239.5M-42.9%
EPS (Basic)$1.01-13.7%$1.03+33.8%$1.22+32.6%$0.71-40.8%$1.17-4.9%$0.77-34.7%$0.92+9.5%$1.20-40.6%
EPS (Diluted)$1.00-13.8%$1.03+33.8%$1.22+34.1%$0.71-40.3%$1.16-5.7%$0.77-34.7%$0.91+8.3%$1.19-40.5%
Diluted Shares (Avg)191M-3.7%193M-2.8%196M-2.0%N/A199M-2.1%198M-3.9%200M-3.2%N/A

Not reported in any period shown, so not listed: Interest Expense.

ZBH Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ZBH quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Total Assets$23.5B+0.2%$22.8B-0.3%$22.7B+2.4%$23.1B+8.1%$23.5B+8.1%$22.9B+6.3%$22.2B+3.4%$21.4B-0.6%
Current Assets$5.1B-12.1%$5.1B+0.8%$5.0B-11.2%$5.1B+9.6%$5.8B+20.0%$5.1B+8.9%$5.6B+20.7%$4.7B+1.3%
Cash & Equivalents$399.9M-69.1%$410.0M-26.4%$424.2M-69.4%$591.9M+12.6%$1.3B+127.2%$556.9M+32.6%$1.4B+252.3%$525.5M+26.4%
Short-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Inventory$2.4B-4.7%$2.3B-7.5%$2.2B+0.1%$2.3B+2.3%$2.5B+4.9%$2.5B+3.6%$2.2B-6.0%$2.2B-6.3%
Accounts Receivable$1.8B+13.6%$1.8B+9.8%$1.7B+12.7%$1.7B+15.1%$1.6B+7.9%$1.6B+13.6%$1.5B+6.0%$1.5B+2.7%
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Goodwill$10.3B+6.5%$9.9B+2.2%$9.9B+10.5%$9.9B+11.1%$9.7B+8.9%$9.7B+10.0%$9.0B+2.2%$9.0B+1.5%
Total Liabilities$10.8B+0.8%$10.2B-1.6%$10.0B+2.7%$10.4B+16.8%$10.7B+14.8%$10.3B+17.8%$9.8B+10.6%$8.9B-1.3%
Current Liabilities$3.5B+45.8%$3.0B+11.6%$2.9B+24.8%$2.6B+5.4%$2.4B-32.7%$2.7B-25.2%$2.3B-18.0%$2.5B-14.2%
Non-Current Liabilities$7.3B-12.1%$7.2B-6.3%$7.2B-4.1%$7.8B+21.2%$8.3B+44.3%$7.6B+47.8%$7.5B+23.7%$6.4B+4.7%
Long-Term Debt$6.2B-17.3%$6.3B-7.0%$6.3B-4.3%$6.9B+29.8%$7.5B+58.6%$6.8B+70.7%$6.6B+36.3%$5.3B+9.7%
Total Equity$12.7B-0.3%$12.6B+0.8%$12.7B+2.2%$12.7B+1.8%$12.8B+3.1%$12.5B-1.7%$12.4B-1.6%$12.5B-0.1%
Retained Earnings$12.1B+5.1%$12.0B+5.5%$11.8B+5.1%$11.6B+4.6%$11.5B+5.6%$11.3B+5.9%$11.2B+6.9%$11.1B+6.8%

ZBH Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ZBH quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow$560.0M+33.7%$447.8M+18.4%$359.4M-6.1%$517.4M+2.2%$418.7M+5.8%$378.2M+2.4%$382.8M+67.9%$506.3M-14.0%
Depreciation & Amortization$282.0M-0.6%$270.8M-0.4%$270.0M+6.1%$284.0M+7.7%$283.6M+13.0%$271.8M+11.8%$254.4M+6.6%$263.6M+9.3%
Stock-Based CompensationN/AN/A$24.2M+23.5%N/AN/AN/A$19.6M-32.4%N/A
Capital Expenditures$75.8M+37.8%$54.2M+8.2%$36.3M-18.6%$74.8M+45.2%$55.0M+23.6%$50.1M-4.9%$44.6M-19.1%$51.5M-18.0%
Free Cash Flow$484.2M+33.1%$393.6M+20.0%$323.1M-4.5%$442.6M-2.7%$363.7M+3.6%$328.1M+3.6%$338.2M+95.6%$454.8M-13.5%
Investing Cash Flow-$543.3Mn/m-$190.8Mn/m-$159.0Mn/m-$322.0Mn/m-$163.3Mn/m-$1.4Bn/m-$106.0Mn/m-$291.2Mn/m
Financing Cash Flow-$27.2M-105.6%-$271.1M-265.5%-$369.2M-164.2%-$897.0Mn/m$483.8Mn/m$163.8Mn/m$575.4Mn/m-$240.6Mn/m
Dividends Paid$45.8M-3.6%$46.5M-2.1%$46.9M-1.9%$47.5M-1.0%$47.5M-3.5%$47.5M-3.8%$47.8M-3.2%$48.0M-4.4%
Share Buybacks$78.5Mn/m$250.7M+3381.9%$250.1M+8.8%$250.0M+246.3%$0-100.0%$7.2M-91.6%$229.8M+102.3%$72.2M-82.4%

ZBH Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ZBH quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Gross Margin71.2%-0.9pp70.8%-0.7pp72.4%+1.2pp64.7%-6.3pp72.0%+1.6pp71.5%0.0pp71.2%-1.7pp71.0%-1.2pp
Operating Margin14.9%-2.6pp15.0%+0.5pp17.9%+2.6pp6.9%-12.3pp17.5%+2.2pp14.4%-3.7pp15.3%+1.2pp19.2%+1.0pp
Net Margin9.3%-2.3pp9.1%+1.8pp11.4%+1.9pp6.2%-5.6pp11.5%-2.1pp7.4%-5.1pp9.5%+0.4pp11.8%-9.8pp
Return on Equity1.5%-0.3pp1.6%+0.3pp1.9%+0.4pp1.1%-0.8pp1.8%-0.2pp1.2%-0.7pp1.5%+0.1pp1.9%-1.4pp
Return on Assets0.8%-0.2pp0.9%+0.2pp1.1%+0.2pp0.6%-0.5pp1.0%-0.2pp0.7%-0.5pp0.8%0.0pp1.1%-0.8pp
Current Ratio1.46-1.0x1.69-0.2x1.73-0.7x1.98+0.1x2.43+1.1x1.87+0.6x2.44+0.8x1.91+0.3x
Debt-to-Equity0.49-0.1x0.500.0x0.500.0x0.55+0.1x0.59+0.2x0.54+0.2x0.53+0.1x0.430.0x
Liabilities-to-Equity0.850.0x0.810.0x0.790.0x0.82+0.1x0.84+0.1x0.82+0.1x0.79+0.1x0.710.0x
Asset Turnover0.090.0x0.100.0x0.090.0x0.100.0x0.090.0x0.090.0x0.090.0x0.090.0x
FCF Margin23.5%+5.3pp18.1%+2.3pp15.5%-2.2pp19.7%-2.7pp18.2%-1.1pp15.8%-0.5pp17.7%+8.6pp22.5%-4.6pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Zimmer Biomet Holdings, Inc. ZBH FY2025 $8.2B $705.1M 8.6% $19.3B 60/100
STERIS plc STE FY2026 $5.9B $782.3M 13.2% $25.0B 68/100
Glaukos Corporation GKOS FY2025 $507.4M -$187.7M -37.0% $14.4B 51/100
Smith & Nephew plc SNN FY2025 $6.2B $625.0M 10.1% $12.8B 62/100
DexCom, Inc. DXCM FY2025 $4.7B $836.3M 17.9% $30.6B 74/100
Koninklijke Philips N.V. PHG FY2025 $20.9B $1.1B 5.0% $29.2B 36/100

Frequently Asked Questions

Zimmer Biomet Holdings, Inc. (ZBH) reported $8.2B in total revenue for fiscal year 2025. This represents a 7.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Zimmer Biomet Holdings, Inc. (ZBH) revenue grew by 7.2% year-over-year, from $7.7B to $8.2B in fiscal year 2025.

Yes, Zimmer Biomet Holdings, Inc. (ZBH) reported a net income of $767.4M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net income of $705.1M, with a net profit margin of 8.6%.

Zimmer Biomet Holdings, Inc. (ZBH) reported diluted earnings per share of $3.55 for fiscal year 2025. This represents a -19.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Zimmer Biomet Holdings, Inc. (ZBH) had EBITDA of $2.2B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2025, Zimmer Biomet Holdings, Inc. (ZBH) had $591.9M in cash and equivalents against $6.9B in long-term debt.

Zimmer Biomet Holdings, Inc. (ZBH) had a gross margin of 69.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

Zimmer Biomet Holdings, Inc. (ZBH) had an operating margin of 13.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

Zimmer Biomet Holdings, Inc. (ZBH) had a net profit margin of 8.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Yes, Zimmer Biomet Holdings, Inc. (ZBH) paid $0.96 per share in dividends during fiscal year 2025.

Zimmer Biomet Holdings, Inc. (ZBH) has a return on equity of 5.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Zimmer Biomet Holdings, Inc. (ZBH) generated $1.5B in free cash flow during fiscal year 2025. This represents a 13.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Zimmer Biomet Holdings, Inc. (ZBH) generated $1.7B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Zimmer Biomet Holdings, Inc. (ZBH) had $23.1B in total assets as of fiscal year 2025, including both current and long-term assets.

Zimmer Biomet Holdings, Inc. (ZBH) invested $224.5M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Zimmer Biomet Holdings, Inc. (ZBH) invested $458.5M in research and development during fiscal year 2025.

Yes, Zimmer Biomet Holdings, Inc. (ZBH) spent $487.0M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Zimmer Biomet Holdings, Inc. (ZBH) had 196M shares outstanding as of fiscal year 2025.

Zimmer Biomet Holdings, Inc. (ZBH) had a current ratio of 1.98 as of fiscal year 2025, which is generally considered healthy.

Zimmer Biomet Holdings, Inc. (ZBH) had a debt-to-equity ratio of 0.55 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.

Zimmer Biomet Holdings, Inc. (ZBH) had a liabilities-to-equity ratio of 0.82 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.

Zimmer Biomet Holdings, Inc. (ZBH) had a return on assets of 3.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Zimmer Biomet Holdings, Inc. (ZBH) trades at 25.2x earnings, its market capitalization divided by $767.4M net income, trailing 12 months to September 30, 2026. The market capitalization is $19.3B as of Nov 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Zimmer Biomet Holdings, Inc. (ZBH) trades at 2.3x sales, its market capitalization divided by $8.6B revenue, trailing 12 months to September 30, 2026. The market capitalization is $19.3B as of Nov 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Zimmer Biomet Holdings, Inc. (ZBH) has an Altman Z-Score of 2.47, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Zimmer Biomet Holdings, Inc. (ZBH) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Zimmer Biomet Holdings, Inc. (ZBH) has an earnings quality ratio of 2.41x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Zimmer Biomet Holdings, Inc. (ZBH) scores 60 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top